关于
  • English
  • About
    • About Sirona
    • Management
    • Board of Directors
    • Strategic Advisory Board
    • Our Partners
  • TFChem
    • About TFChem
    • Management
    • Team
    • TFChem Laboratory Capabilities
  • Programs
    • Proprietary Platform Technology
    • Pipeline
    • Diabetes – SGLT2 Inhibitor
    • Skincare – Dark Spot Correction
    • Skincare – Anti-Aging / Anti-Wrinkle
    • Antiviral
  • News
    • Sirona News
    • Events
  • Investors
    • Financial Information
    • Financial Reports
    • Investor & Media Kit
    • Newsletter
  • Contact
  • Careers

News

Sirona Biochem Closes Non-Brokered Private Placement of CDN$1,406,500

March 23rd, 2012

Vancouver, British Columbia – March 23, 2012 – Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), (the “Company”) is pleased to announce that on March 23, 2012 it completed the sale of 14,065,000 units (each a “Unit”) at a price of $0.10 per Unit for total proceeds of CDN$1,406,500 (the “Private Placement”).  Each Unit consists of one common share of the Company (a “Share”) and one transferable share purchase warrant (a “Warrant”).  Each Warrant entitles the holder to purchase one additional common share (a “Warrant Share”) of the Company at any time for two years from the closing date of the Private Placement at a price of $0.18 per Warrant Share.

In connection with closing the Private Placement, the Company has agreed to pay finders’ fees in the aggregate amount of $76,000 in cash to various finders (the “Finders”) for their efforts in sourcing purchasers for the Private Placement.  The Finders will also receive 760,000 non transferable finders’ warrants (each a “Finder’s Warrant”) representing 8% of the Units placed by each Finder.  Each Finder’s Warrant entitles the holder to purchase one common share (a “Finder’s Warrant Share”) at an exercise price of $0.18 per Finder’s Warrant Share until March 23, 2014.

All securities are subject to a four-month and one day hold period expiring on July 24, 2012.

The Company intends to use the proceeds from the Private Placement for general working capital.

 

About Sirona Biochem Corp.

Sirona Biochem Corp. is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Julie Jang Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com

Archives

  • About
  • TFChem
  • Programs
  • News
  • Investors
  • Contact

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

Enter your info below to subscribe to our newsletter:
Loading